Endonovo Launches Telehealth Initiative
December 13, 2022 09:11 ET
|
Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
October 19, 2021 12:22 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
July 06, 2021 14:34 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
April 26, 2021 09:41 ET
|
SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...
Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
March 01, 2021 12:21 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
January 25, 2021 09:00 ET
|
Neuropathix, Inc.
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...
Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development
July 29, 2020 07:00 ET
|
Melt Pharmaceuticals
FDA has accepted MELT-100 IND; Phase 1 study enrollment to start immediately BOSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing...
TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy
May 31, 2020 00:09 ET
|
TLC
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
February 27, 2020 15:30 ET
|
Sorrento Therapeutics, Inc.
Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...